Literature DB >> 20714888

Genetic variants affecting incretin sensitivity and incretin secretion.

K Müssig1, H Staiger, F Machicao, H-U Häring, A Fritsche.   

Abstract

Recent genome-wide association studies identified several novel risk genes for type 2 diabetes. The majority of these type 2 diabetes risk variants confer impaired pancreatic beta cell function. Though the molecular mechanisms by which common genetic variation within these loci affects beta cell function are not completely understood, risk variants may alter glucose-stimulated insulin secretion, proinsulin conversion, and incretin signals. In humans, the incretin effect is mediated by the secretion and insulinotropic action of two peptide hormones, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. This review article aims to give an overview of the type 2 diabetes risk loci that were found to associate with incretin secretion or incretin action, paying special attention to the potential underlying mechanisms.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20714888     DOI： 10.1007/s00125-010-1876-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


  100 in total

1.  Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.

Authors:  Jose C Florez; Kathleen A Jablonski; Steven E Kahn; Paul W Franks; Dana Dabelea; Richard F Hamman; William C Knowler; David M Nathan; David Altshuler
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

2.  Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance.

Authors:  Coleen M Damcott; Toni I Pollin; Laurie J Reinhart; Sandra H Ott; Haiqing Shen; Kristi D Silver; Braxton D Mitchell; Alan R Shuldiner
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

3.  Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.

Authors:  K Miyawaki; Y Yamada; H Yano; H Niwa; N Ban; Y Ihara; A Kubota; S Fujimoto; M Kajikawa; A Kuroe; K Tsuda; H Hashimoto; T Yamashita; T Jomori; F Tashiro; J Miyazaki; Y Seino
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53).

Authors:  A L Gloyn; Y Hashim; S J Ashcroft; R Ashfield; S Wiltshire; R C Turner
Journal:  Diabet Med       Date:  2001-03       Impact factor: 4.359

5.  WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain.

Authors:  K Takeda; H Inoue; Y Tanizawa; Y Matsuzaki; J Oba; Y Watanabe; K Shinoda; Y Oka
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

6.  The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

Authors:  Giorgio Sesti; Emanuela Laratta; Marina Cardellini; Francesco Andreozzi; Silvia Del Guerra; Concetta Irace; Agostino Gnasso; Maria Grupillo; Renato Lauro; Marta Letizia Hribal; Francesco Perticone; Piero Marchetti
Journal:  J Clin Endocrinol Metab       Date:  2006-04-04       Impact factor: 5.958

7.  Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance.

Authors:  Alena Stancáková; Jussi Pihlajamäki; Johanna Kuusisto; Norbert Stefan; Andreas Fritsche; Hans Häring; Francesco Andreozzi; Elena Succurro; Giorgio Sesti; Trine Welløv Boesgaard; Torben Hansen; Oluf Pedersen; Per Anders Jansson; Ann Hammarstedt; Ulf Smith; Markku Laakso
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

8.  A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study.

Authors:  Harald Staiger; Alena Stancáková; Jone Zilinskaite; Markku Vänttinen; Torben Hansen; Maria Adelaide Marini; Ann Hammarstedt; Per-Anders Jansson; Giorgio Sesti; Ulf Smith; Oluf Pedersen; Markku Laakso; Norbert Stefan; Andreas Fritsche; Hans-Ulrich Häring
Journal:  Diabetes       Date:  2007-11-26       Impact factor: 9.461

9.  Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.

Authors:  Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

10.  TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels.

Authors:  C H Kimber; A S F Doney; E R Pearson; M I McCarthy; A T Hattersley; G P Leese; A D Morris; C N A Palmer
Journal:  Diabetologia       Date:  2007-04-11       Impact factor: 10.122
View more
  16 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges.

Authors:  Yuan Lin; Jennifer Wessel
Journal:  Curr Diab Rep       Date:  2019-02-26       Impact factor: 4.810

Review 3.  Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond.

Authors:  Niels Grarup; Camilla H Sandholt; Torben Hansen; Oluf Pedersen
Journal:  Diabetologia       Date:  2014-05-24       Impact factor: 10.122

4.  β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.

Authors:  Benedikt A Aulinger; Torsten P Vahl; Hilary E Wilson-Pérez; Ron L Prigeon; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2015-03-31       Impact factor: 5.958

Review 5.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 6.  Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.

Authors:  Mariana Murea; Lijun Ma; Barry I Freedman
Journal:  Rev Diabet Stud       Date:  2012-05-10

Review 7.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

8.  Hypoglycemia after gastric bypass: the dark side of GLP-1.

Authors:  Mary-Elizabeth Patti; Allison B Goldfine
Journal:  Gastroenterology       Date:  2014-01-24       Impact factor: 22.682

9.  The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.

Authors:  Leen M 't Hart; Andreas Fritsche; Giel Nijpels; Nienke van Leeuwen; Louise A Donnelly; Jacqueline M Dekker; Marjan Alssema; Joao Fadista; Françoise Carlotti; Anette P Gjesing; Colin N A Palmer; Timon W van Haeften; Silke A Herzberg-Schäfer; Annemarie M C Simonis-Bik; Jeanine J Houwing-Duistermaat; Quinta Helmer; Joris Deelen; Bruno Guigas; Torben Hansen; Fausto Machicao; Gonneke Willemsen; Robert J Heine; Mark H H Kramer; Jens J Holst; Eelco J P de Koning; Hans-Ulrich Häring; Oluf Pedersen; Leif Groop; Eco J C de Geus; P Eline Slagboom; Dorret I Boomsma; Elisabeth M W Eekhoff; Ewan R Pearson; Michaela Diamant
Journal:  Diabetes       Date:  2013-05-14       Impact factor: 9.461

Review 10.  Untangling the interplay of genetic and metabolic influences on beta-cell function: Examples of potential therapeutic implications involving TCF7L2 and FFAR1.

Authors:  Robert Wagner; Harald Staiger; Susanne Ullrich; Norbert Stefan; Andreas Fritsche; Hans-Ulrich Häring
Journal:  Mol Metab       Date:  2014-01-22       Impact factor: 7.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.